-
公开(公告)号：US20130137752A1
公开(公告)日：2013-05-30
申请号：US13813465
申请日：2011-08-02
申请人： Duncan Brown , James J. Cunningham , Marian Gindy , Victoria Pickering , Matthew G. Stanton , Steven M. Stirdivant , Walter R. Strapps
发明人： Duncan Brown , James J. Cunningham , Marian Gindy , Victoria Pickering , Matthew G. Stanton , Steven M. Stirdivant , Walter R. Strapps
IPC分类号： C12N15/113
CPC分类号： C12N15/1138 , C12N15/113 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/332 , C12N2310/346 , C12N2310/3521 , C12N2320/32
摘要： The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression.
-
2.发明授权RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) 有权使用短干扰核酸（siNA）的RNA干扰介导的连环素（钙粘蛋白相关蛋白），β1（CTNNB1）基因表达的抑制公开(公告)号：US08518907B2
公开(公告)日：2013-08-27
申请号：US13813465
申请日：2011-08-02
申请人： Duncan Brown , James J. Cunningham , Marian Gindy , Victoria Pickering , Matthew G. Stanton , Steven M. Stirdivant , Walter R. Strapps
发明人： Duncan Brown , James J. Cunningham , Marian Gindy , Victoria Pickering , Matthew G. Stanton , Steven M. Stirdivant , Walter R. Strapps
CPC分类号： C12N15/1138 , C12N15/113 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/332 , C12N2310/346 , C12N2310/3521 , C12N2320/32
摘要： The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression.
摘要翻译： 本发明涉及用于研究，诊断和治疗对CTNNB1基因表达和/或活性的调节作用和/或调节β-连环蛋白基因表达途径的性状，疾病和病症的化合物，组合物和方法 。 具体地说，本发明涉及包括小核酸分子，如短干扰核酸（siNA），短干扰RNA（siRNA），双链RNA（dsRNA），微RNA（miRNA）等双链核酸分子， 和能够介导或介导针对CTNNB1基因表达的RNA干扰（RNAi）的短发夹RNA（shRNA）分子。
-
3.发明授权RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) 有权RNA干扰介导使用短干扰核酸（siNA）抑制基因表达公开(公告)号：US09260471B2
公开(公告)日：2016-02-16
申请号：US13881415
申请日：2011-10-25
申请人： Mark Cancilla , James J. Cunningham , Michael W. Flanagan , Henry J. Haringsma , Denise Kenski , Matthew G. Stanton , Steven M. Stirdivant , Aarron Willingham
发明人： Mark Cancilla , James J. Cunningham , Michael W. Flanagan , Henry J. Haringsma , Denise Kenski , Matthew G. Stanton , Steven M. Stirdivant , Aarron Willingham
CPC分类号： C12N15/113 , C07H21/02 , C12N15/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3231 , C12N2310/331 , C12N2310/344 , C12N2310/346 , C12N2310/351 , C12N2320/32 , C12N2320/51 , C12N2310/3527 , C12N2310/3521 , C12N2310/322 , C12N2310/3533
摘要： The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
摘要翻译： 本发明涉及用于研究，诊断和治疗响应于基因表达和/或活性的调节和/或调节基因表达途径的性状，疾病和病症的化合物，组合物和方法。 具体地说，本发明涉及包括小核酸分子的双链核酸分子，例如能够介导或介导针对靶基因表达的RNA干扰（RNAi）的短干扰核酸（siNA）分子。
-
4.发明申请RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) 有权RNA干扰介导的使用短暂干扰核酸的基因表达的抑制（siNA）公开(公告)号：US20130217756A1
公开(公告)日：2013-08-22
申请号：US13881415
申请日：2011-10-25
申请人： Mark Cancilla , James John Cunningham , Michael W. Flanagan , Henry J. Haringsma , Denise M. Kenski , Matthew G. Stanton , Steven M. Stirdivant , Aarron T. Willingham
发明人： Mark Cancilla , James John Cunningham , Michael W. Flanagan , Henry J. Haringsma , Denise M. Kenski , Matthew G. Stanton , Steven M. Stirdivant , Aarron T. Willingham
IPC分类号： C07H21/02
CPC分类号： C12N15/113 , C07H21/02 , C12N15/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3231 , C12N2310/331 , C12N2310/344 , C12N2310/346 , C12N2310/351 , C12N2320/32 , C12N2320/51 , C12N2310/3527 , C12N2310/3521 , C12N2310/322 , C12N2310/3533
摘要： The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
摘要翻译： 本发明涉及用于研究，诊断和治疗响应于基因表达和/或活性的调节和/或调节基因表达途径的性状，疾病和病症的化合物，组合物和方法。 具体地说，本发明涉及包括小核酸分子的双链核酸分子，例如能够介导或介导针对靶基因表达的RNA干扰（RNAi）的短干扰核酸（siNA）分子。
-
公开(公告)号：US5690928A
公开(公告)日：1997-11-25
申请号：US224422
申请日：1994-04-11
IPC分类号： A61K38/00 , A61K47/48 , A61P35/00 , C07K1/22 , C07K1/30 , C07K14/00 , C07K14/195 , C07K14/21 , C07K14/41 , C07K14/415 , C07K14/495 , C07K14/52 , C07K19/00 , C12N5/10 , C12N15/09 , C12P21/02 , C12R1/19 , A61K38/45
CPC分类号： C07K14/495 , A61K47/48261 , A61K47/48269 , C07K14/21 , A61K38/00 , C07K2319/00
摘要： Methods and compositions for treating bladder cancer using TGF-alpha or EGF fused to PE.sub.40 or cysteine modified derivatives are taught. Also, a method of producing TGF-alpha-PE.sub.40 derivatives of enhanced potency is described.
摘要翻译： 教导了使用与PE40或半胱氨酸修饰的衍生物融合的TGF-α或EGF治疗膀胱癌的方法和组合物。 另外，描述了提高效能的TGF-α-PE40衍生物的生产方法。
-
公开(公告)号：US5621078A
公开(公告)日：1997-04-15
申请号：US391259
申请日：1995-02-21
IPC分类号： A61K47/48 , C07K14/21 , C07K14/485 , C07K14/495
CPC分类号： B82Y5/00 , A61K47/48353 , A61K47/48484 , C07K14/21 , C07K14/485 , C07K14/495 , C07K2319/00
摘要： Pseudomonas exotoxin 40 is modified by deleting or substituting one or more cysteine residues. Such a modified protein, when hybridized to TGF.alpha., exhibits altered biological activities from unmodified TGF.alpha. PE.sub.40, including decreased cell killing activity and increased receptor-binding activity.
摘要翻译： 通过缺失或取代一个或多个半胱氨酸残基来修饰假单胞菌外毒素40。 当与TGFα杂交时，这种修饰的蛋白质表现出来自未修饰的TGFαPE40的改变的生物活性，包括降低的细胞杀伤活性和增加的受体结合活性。
-
公开(公告)号：US5912322A
公开(公告)日：1999-06-15
申请号：US839425
申请日：1997-04-14
IPC分类号： A61K47/48 , C07K14/21 , C07K14/485 , C07K14/495 , C07K14/00 , C12N15/00
CPC分类号： B82Y5/00 , A61K47/48353 , A61K47/48484 , C07K14/21 , C07K14/485 , C07K14/495 , C07K2319/00
摘要： Psuedomonas exotoxin 40 is modified by deleting or substituting one or more cysteine residues. Such a modified protein may be incorporated into a fusion protein with TGF.alpha.. The resulting fusion protein exhibits altered biological activities from unmodified TGF.alpha.-PE.sub.40, including decreased cell killing activity and increase receptor-binding activity.
摘要翻译： 通过删除或取代一个或多个半胱氨酸残基来修饰Psuedomonas外毒素40。 这种修饰的蛋白质可以掺入到具有TGFα的融合蛋白中。 所得的融合蛋白表现出来自未修饰的TGFα-PE40的生物活性改变，包括降低的细胞杀伤活性和增加受体结合活性。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.054 秒)
